NCT04813640.

Study name	Eye length signal with myopia control
Methods	Randomised parallel‐group design
Participants	Inclusion criteria: aged 7‐14 years,spherical component −0.50 D to −4.50 D, astigmatism ≤ −1.50 D, ocular health findings considered to be "normal". Correctable vision to at least 6/9.5 (20/30) or better in each eye with spectacles Exclusion criteria: known allergy to, or a history of intolerance to tropicamide or topical anaesthetics, strabismus and/or amblyopia, previous eye surgery (including strabismus surgery), any ocular, systemic or other condition or disease with possible associations with myopia or affecting refractive development e.g. Marfan syndrome, retinopathy of prematurity, diabetes, any ocular injury or condition (including keratoconus and herpes keratitis) of the cornea, conjunctiva or eyelids, worn BFs or PALs, worn OK or BF contact lenses, current orthoptic treatment or vision training
Interventions	Intervention: novel myopia control spectacles (Prototype 1) Intervention: novel myopia control spectacles (Prototype 2) Intervention: commercially available myopia control spectacles Comparator intervention: SVLs
Outcomes	Primary outcome: change in AL Secondary outcome: vision and choroidal physiology Maximum follow up: 6 months
Starting date	February 2021 Estimated end date: October 2021
Contact information	clinicaltrials.gov/ct2/show/NCT04813640
Notes